and O.K.; writingreview and editing. discharged and 14 died. Both the absence of anti-S SARS-CoV-2 antibodies and poor clinical outcomes of COVID-19 disease were associated with older age, lower Ct values, and a shorter period between symptom onset and hospital admission. Ct values and time between symptom onset and hospitalization were independently associated Tesevatinib with SARS-CoV-2 IgG S responses upon admission. The PaO2/FiO2 ratio was identified as an independent predictor of in-hospital mortality. Conclusions: Host- and disease-associated factors can predict SARS-CoV-2 IgG S responses and mortality in hospitalized patients with breakthrough SARS-CoV-2 Infection. 0.05 level. 3. Results 3.1. Baseline Characteristics of the Study Population The mean age of participants was 72.44 1.22 years. Seventy-three subjects had received the BNT162b2/Pfizer vaccine, 22 the Vaxzevria, ChAdOx1-S/AstraZeneca vaccine, and 3 the Johnson & Johnsons Janssen COVID-19 Vaccine (information regarding the type of COVID-19 vaccine was unavailable for four subjects). The mean number Tesevatinib of days since completion of vaccination was 159.03 6.35. The mean real time PCR cycle threshold (Ct) value was 20.01 0.54. The baseline laboratory characteristics of the study population are presented in Table 2. Table 2 Baseline characteristics of the study population (= 102). = 27)= 75)Value= 14)= 88)Value 0.001). Compared to cases with detectable antibody levels, cases with a negative antibody test were older (= 0.039) and had a Tesevatinib higher creatinine level on admission (= 0.001). The same group of patients was also observed to have lower Ct values ( 0.001) and a shorter duration between symptom onset and hospital admission ( 0.001). The absence of anti-S SARS CoV-2-antibodies on the first day of hospitalization was also associated with the presence of diabetes (= 0.006), PaO2/FiO2 (PF) ratio values 150 mm Hg (= 0.014), and death (= 0.019) (Table 2). The Ct values and time between Tesevatinib symptom onset and hospitalization remained significant in the multiple regression analysis (= 0.023 and = 0.025, respectively) (Table 3). Table 3 Results of the multiple regression analysis with respect to the variables affecting the presence of anti-S SARS-CoV-2 antibodies upon admission. Value= 0.035). Poor disease outcome was associated with older age (= 0.003), lower Ct values (= 0.036), a shorter duration between symptom onset and hospital admission (= 0.007), and lower BMI (= 0.029). Non-deceased patients were more likely to have hypertension (= 0.014) and PF ratio values 150 mm Hg ( 0.001) (Table 2). The PF ratio was identified by the multiple logistic regression model as an independent predictor of in-hospital mortality (= 0.001) (Table 4). The vaccine type variable was not included in the multiple regression analysis since none of the deceased patients had received a viral vector COVID-19 vaccine. Table 4 Results of the multiple regression analysis with respect to the variables affecting the outcome of COVID-19 disease in fully vaccinated, hospitalized patients. Value /th th rowspan=”2″ align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” colspan=”1″ Exp (B) /th th colspan=”2″ align=”center” valign=”middle” style=”border-top:solid thin;border-bottom:solid thin” rowspan=”1″ 95% C.I. for EXP(B) ** /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Lower /th th align=”center” valign=”middle” style=”border-bottom:solid thin” rowspan=”1″ colspan=”1″ Upper /th /thead age0.0690.0531.72110.1901.0710.9671.188Ct?0.2160.1482.13510.1440.8060.6031.077Days_WSBH *?0.0590.3060.03710.8470.9430.5171.718BMI?0.2350.1602.15910.1420.7910.5781.081antibodies (1)?0.2751.1940.05310.8180.7600.0737.893PF_Ratio (1)?4.1561.4428.30510.0040.0160.0010.265Hypertension (1)1.1151.1850.88510.3473.0500.29931.135Constant4.0958.2900.24410.62160.068 Open in a separate window Dependent variable: Mortality; Parameter coding (1): No detection of antibodies, non-hypertensive, PF ratio 150 mm Hg. * Days between symptom onset and hospitalization, ** B; the coefficient for the constant, S.E.; the standard error for B, Wald; the Wald chi-square test, df; STMY the degrees of freedom for the Wald chi-square test, Exp(B); The exponentiation of the B coefficient, C.I; confidence interval. 4. Discussion To our knowledge, this is the first study Tesevatinib to assess several factors affecting SARS-CoV-2 IgG S antibody responses in fully vaccinated COVID-19 patients needing hospitalization due to severe.